Patients fear rising costs as Eli Lilly adjusts pricing for its obesity drug Zepbound.

  • Eli Lilly raises the price of Zepbound under its savings-card program from $550 to $650.
  • Patients without insurance coverage for Zepbound are concerned about affordability.
  • Only one-third of employer plans cover GLP-1 drugs for weight loss.
  • The introduction of single-dose vials is seen as a positive step, but coverage issues remain.
  • Patients are frustrated with the disconnect between the health benefits of obesity drugs and insurance coverage.

Eli Lilly & Co. recently announced changes to the pricing and packaging of its weight-loss drug Zepbound, claiming to expand access for those living with obesity. However, many patients are worried that these changes will make the medication less affordable. The cost for a one-month prescription under Lilly’s savings-card program has increased from $550 to $650 for those without insurance coverage for Zepbound. While Lilly highlighted the introduction of single-dose vials priced at $399 and $549, they did not address the price hike for the savings-card program. A Lilly spokesperson stated that the increase is necessary to maintain the program’s sustainability as more commercially insured individuals gain coverage for Zepbound, allowing them to pay as little as $25 per month. Patients who were already enrolled in the savings-card program can continue to pay the previous price until the end of the year. However, some patients, like Eli Greenberg from Minneapolis, experienced pricing issues when trying to fill their prescriptions, leading to confusion and frustration. Many patients have taken to online forums to express their disappointment, with some stating that the new price has priced them out of the medication. Despite the challenges, Lilly is exploring ways to address the lack of insurance coverage for obesity medications. A recent survey revealed that only about one-third of employer plans cover GLP-1 drugs for weight loss, a slight increase from last year but still significantly lower than coverage for diabetes medications. Experts acknowledge that while the new single-dose vials are a step forward, systemic issues with obesity drug coverage persist. The vials may also be beneficial for Medicare patients who are not eligible for savings cards. However, the transition to using needles and syringes instead of injector pens may deter some patients. Eli Lilly continues to evaluate market conditions to ensure that patients can affordably access Zepbound.·

Image Credits: no
Factuality Level: 7
Factuality Justification: The article provides a detailed account of Eli Lilly’s pricing changes for Zepbound and includes patient experiences, expert opinions, and relevant statistics. However, it contains some subjective statements and anecdotal evidence that may introduce bias. While the information is mostly accurate, the focus on individual frustrations and the lack of comprehensive coverage of the broader implications could mislead readers about the overall situation.·
Noise Level: 7
Noise Justification: The article provides a detailed account of Eli Lilly’s pricing changes for Zepbound, highlighting patient experiences and the implications of these changes on access to medication. It includes relevant data on insurance coverage and expert opinions, which adds depth to the analysis. However, it could benefit from a more critical examination of the broader systemic issues in healthcare access and pricing.·
Public Companies: Eli Lilly & Co. (LLY), Amazon.com, Inc. (AMZN)
Key People: Eli Greenberg (Patient), James Zervios (Chief Operating Officer of the Obesity Action Coalition), Caroline Apovian (Co-Director of the Center for Weight Management and Wellness at Brigham and Women’s Hospital and Professor at Harvard Medical School)

Track all markets on TradingView

Financial Relevance: Yes
Financial Markets Impacted: Eli Lilly & Co.
Financial Rating Justification: The article discusses pricing and packaging changes for the weight-loss drug Zepbound by Eli Lilly & Co., which impacts the company’s financial situation and may affect its sales and revenue. Additionally, it mentions the stock performance of Eli Lilly, highlighting its relevance to financial topics.
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Extreme Rating Justification: The article discusses pricing changes for a medication and the impact on patients, but it does not report on any extreme event that occurred in the last 48 hours.·
Move Size: No market move size mentioned.
Sector: Healthcare
Direction: Down
Magnitude: Medium
Affected Instruments: Stocks

Reported publicly: www.marketwatch.com